Relafen 750, a novel compound of naproxen, represents a fascinating case from our biochemical pharmacy perspective. Its mechanism of action, primarily involving blocking of cyclooxygenase enzymes – COX-1 and COX-2 – contributes to significant decrease in prostaglandin creation. Considering the biochemical framework, the drug's potency is direct